Lymphoma

After nearly 11 years of living with Hodgkin lymphoma, my sister Kathleen passed away peacefully at 39, leaving me to navigate the sorrow of losing her.

Daniel Jernazian, a two-time cancer survivor, shares how sports, advocacy and meeting his idol shaped his journey through illness and recovery.

Mark Daniels, 83, says CAR T-cell therapy and strong support helped him overcome lymphoma twice and return to the fitness-focused life he values.

The 2025 ASCO Annual Meeting brought many different updates to light in the realm of hematological malignancies, including multiple myeloma and lymphoma.

The FDA approved Monjuvi with Revlimid and Rituxan for R/R follicular lymphoma after it showed significantly longer progression-free survival vs placebo.

I was diagnosed with follicular lymphoma in 2020, during COVID, which forced me to retire early and taught me I’m more than a statistic.

I’m working to make cancer treatments less painful by developing donor-derived CAR therapies, so others don’t have to suffer the way I did.

The antibody-drug conjugate zilovertamab vedotin plus Rituxan and chemotherapy showed an objective response rate of 56.3% in relapsed/refractory DLBCL.

The first patient has been dosed in the phase 3 TERZO trial of Copiktra for relapsed or refractory nodal T-follicular helper cell lymphoma.

The dual-targeting CAR T-cell therapy KITE-363 showed positive response rates and manageable side effects in relapsed or refractory B-cell lymphoma.

Columvi plus chemo had enhanced survival outcomes vs Rituxan plus chemo in patients with relapsed/refractory diffuse large B-cell lymphoma.

I’m here to prove that powerful phrase; after nearly 16 years living with incurable cancer, I know there’s more to my story than the statistics.

The phase 1/2 STARLIGHT-1 trial has dosed the first patient in the second cohort of the study evaluating EB103 in advanced B-cell non-Hodgkin’s lymphomas.

Dr. Andrew M. Evens discusses long-term survivorship challenges that can occur among adolescent and young lymphoma survivors.

Dr. Andrew M. Evens discussed the importance of differentiating AYA cancers from other age groups, specifically focusing on lymphoma care.

A patient with relapsed follicular lymphoma achieved complete remission one month after PMB-CT01 treatment in the phase 1 PMB-102 trial.

The FDA'S ODAC has casted their votes on the use of certain treatments in both the relapsed/refractory DLBCL and myeloma patient populations, respectively.

An expert reflects on the treatment landscape of Waldenström macroglobulinemia, emphasizing diagnostics, collaboration and managing neuropathy effectively.

After cancer, lifelong infusions were tough — until nurse Angela’s care and kindness reminded me that true support can last long after treatment ends.

Dr. Kara Kelly discusses the unique challenges that adolescent and young adult patients with cancer face following their diagnosis.

Eric Z. cared for my sister and mentored me with compassion, wisdom and unwavering presence — shaping my path in nursing and life.

Dr. Shirley D'Sa discusses the importance of catching peripheral neuropathy in patients with Waldenström macroglobulinemia early on and how to treat it.

In this Q&A, Carly Stafford Dixon discusses her lymphoma journey, recovery with CAR T therapy, and mission to raise support for young adults with cancer.

Dr. Neha Mehta-Shah shares how patients can better understand their subtype of rare lymphoma, as well as expands on the challenges these patients face.

A patient with heavily pretreated relapsed/refractory diffuse large B-cell lymphoma achieved complete remission following novel in vivo CD19 CAR-T therapy.

In a Phase 1b/2a trial for lymphoma and cytokine release syndrome, the first group's dose-limiting toxicity observation period was successfully completed.

The first patient with relapsed or refractory CD5-positive T-cell lymphoma has been dosed with the CAR-T cell therapy MB-105.

Carly Stafford Dixon, a rare cancer survivor, highlights the need for AYA cancer awareness to improve support, visibility and access to vital resources.

After living with lymphoma for 15 and a half years, my doctor has suggested reducing the dose of my medication and possibly taking me off of it.